• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Williams Patrick F.

    6/24/25 4:32:01 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care
    Get the next $NPCE alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Williams Patrick F.

    (Last) (First) (Middle)
    C/O NEUROPACE, INC.
    455 N. BERNARDO AVENUE

    (Street)
    MOUNTAIN VIEW CA 94043

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    06/20/2025
    3. Issuer Name and Ticker or Trading Symbol
    NeuroPace Inc [ NPCE ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Leah Akin, Attorney-in-Fact 06/24/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NPCE alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $NPCE

    DatePrice TargetRatingAnalyst
    5/28/2025$18.00Buy
    H.C. Wainwright
    1/21/2025$17.00Buy
    UBS
    3/14/2024$16.00 → $20.00Equal Weight → Overweight
    Wells Fargo
    1/30/2024$22.00Outperform
    Leerink Partners
    11/10/2023$11.00Overweight
    Cantor Fitzgerald
    8/24/2023$5.00 → $6.00Underweight → Equal-Weight
    Morgan Stanley
    2/22/2023$10.00Buy
    Lake Street
    4/6/2022$13.00Outperform
    Wolfe Research
    More analyst ratings

    $NPCE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NeuroPace Announces Strategic CFO Transition

      Appoints Patrick F. Williams as Chief Financial Officer Williams Brings a Track Record of Leading Medical Device Public Companies as CFO Rebecca Kuhn Departing Company and Will Remain in Advisory Role MOUNTAIN VIEW, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointment of Mr. Patrick F. Williams as Chief Financial Officer, effective June 20, 2025. Ms. Rebecca Kuhn has entered into an agreement with the Company to depart from her CFO role and serve in an advisory role to the Company for a twelve-month period. "NeuroPace is pleased to have a finan

      6/24/25 4:05:00 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • NeuroPace Secures Up to $75 Million in Debt Financing

      MOUNTAIN VIEW, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company has entered into a new $75 million credit facility with MidCap Financial, consisting of a $60 million term loan and a $15 million revolving credit facility. Proceeds from the new term loan were used to fully repay NeuroPace's term loan with CRG Partners IV, L.P., with proceeds of the new revolving credit facility available for working capital needs and other corporate purposes. "We are pleased to partner with MidCap Financial on this new credit facility, which provides non-dilutiv

      6/4/25 4:09:37 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study

      -- NeuroPace has completed the primary endpoint analysis of the one-year data from the first and only clinical study to evaluate neuromodulation therapy for idiopathic generalized epilepsy -- Study met the 12-week post-implant primary safety endpoint, demonstrating excellent safety outcomes and confirming favorable safety profile of the RNS® System -- Primary effectiveness endpoint did not reach statistical significance in overall study population but showed a statistically significant response in a subset, which represents the majority of participants -- Preliminary data illustrates the overall value of the RNS System to individualize patient treatment over time, showing mor

      5/27/25 8:00:00 AM ET
      $NPCE
      Medical/Dental Instruments
      Health Care

    $NPCE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on NeuroPace with a new price target

      H.C. Wainwright initiated coverage of NeuroPace with a rating of Buy and set a new price target of $18.00

      5/28/25 9:08:28 AM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • UBS initiated coverage on NeuroPace with a new price target

      UBS initiated coverage of NeuroPace with a rating of Buy and set a new price target of $17.00

      1/21/25 8:23:18 AM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • NeuroPace upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded NeuroPace from Equal Weight to Overweight and set a new price target of $20.00 from $16.00 previously

      3/14/24 8:11:10 AM ET
      $NPCE
      Medical/Dental Instruments
      Health Care

    $NPCE
    SEC Filings

    See more

    $NPCE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Neuropace Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - NeuroPace Inc (0001528287) (Filer)

      6/24/25 4:14:32 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • SEC Form 8-K filed by Neuropace Inc.

      8-K - NeuroPace Inc (0001528287) (Filer)

      6/12/25 4:16:43 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • Neuropace Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure

      8-K - NeuroPace Inc (0001528287) (Filer)

      6/4/25 4:35:01 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Williams Patrick F. was granted 51,850 shares (SEC Form 4)

      4 - NeuroPace Inc (0001528287) (Issuer)

      6/24/25 4:32:55 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Williams Patrick F.

      3 - NeuroPace Inc (0001528287) (Issuer)

      6/24/25 4:32:01 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • Director Geiger Uri was granted 12,036 shares (SEC Form 4)

      4 - NeuroPace Inc (0001528287) (Issuer)

      6/24/25 4:30:17 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care

    $NPCE
    Financials

    Live finance-specific insights

    See more
    • NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study

      -- NeuroPace has completed the primary endpoint analysis of the one-year data from the first and only clinical study to evaluate neuromodulation therapy for idiopathic generalized epilepsy -- Study met the 12-week post-implant primary safety endpoint, demonstrating excellent safety outcomes and confirming favorable safety profile of the RNS® System -- Primary effectiveness endpoint did not reach statistical significance in overall study population but showed a statistically significant response in a subset, which represents the majority of participants -- Preliminary data illustrates the overall value of the RNS System to individualize patient treatment over time, showing mor

      5/27/25 8:00:00 AM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • NeuroPace Reports First Quarter 2025 Financial Results

      -- Reported record quarterly revenue of $22.5 million in Q1 2025, driven by increasing market demand for core RNS System products -- -- Increased full-year 2025 revenue guidance to $93 to $97 million -- -- On track to announce topline data from the NAUTILUS pivotal study in the second half of 2025 -- -- Management scheduled to host a conference call today at 4:30 p.m. ET -- MOUNTAIN VIEW, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update. Recent Highlights Revenue g

      5/13/25 4:05:00 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • NeuroPace Provides Update on Tariff Status

      -- Minimal expected impact to operations and financial results -- -- Company to report first quarter 2025 financial results on May 13, 2025 -- MOUNTAIN VIEW, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today provided an update on its exposure to tariffs that have been implemented. While specific policies and timing of implementation remain fluid, NeuroPace expects minimal impact to its operations and financial results. Specifically, NeuroPace manufactures and sells the vast majority of its devices in the United States and has limited supply chain activities outside th

      4/14/25 4:05:00 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care

    $NPCE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Neuropace Inc.

      SC 13G/A - NeuroPace Inc (0001528287) (Subject)

      11/14/24 6:30:12 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Neuropace Inc.

      SC 13G/A - NeuroPace Inc (0001528287) (Subject)

      11/14/24 3:36:16 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Neuropace Inc.

      SC 13G/A - NeuroPace Inc (0001528287) (Subject)

      10/3/24 4:46:48 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care

    $NPCE
    Leadership Updates

    Live Leadership Updates

    See more
    • NeuroPace Announces Strategic CFO Transition

      Appoints Patrick F. Williams as Chief Financial Officer Williams Brings a Track Record of Leading Medical Device Public Companies as CFO Rebecca Kuhn Departing Company and Will Remain in Advisory Role MOUNTAIN VIEW, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointment of Mr. Patrick F. Williams as Chief Financial Officer, effective June 20, 2025. Ms. Rebecca Kuhn has entered into an agreement with the Company to depart from her CFO role and serve in an advisory role to the Company for a twelve-month period. "NeuroPace is pleased to have a finan

      6/24/25 4:05:00 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • NeuroPace Continues to Strengthen Management Team

      MOUNTAIN VIEW, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointment of Amy Treadwell as its new Vice President of Human Resources, effective immediately. "We are excited to have Amy join the team and help us continue to build an engaged, high-performing culture that supports our growth," said Joel Becker, Chief Executive Officer of NeuroPace. "We are at an important point in our growth with a number of significant commercial, operating, and technological opportunities in front of us. We believe Amy's appointment, along with the recent appointments

      10/16/24 4:05:00 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • NeuroPace Strengthens Management Team with Two Key Appointments

      Appointed former key developer of RNS System as new Vice President of Research and Development Appointed former head of commercial marketing for Boston Scientific's DBS franchise as the new Vice President of Marketing MOUNTAIN VIEW, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointments of Brett Wingeier as the new Vice President of Research and Development and Katie Keller as the new Vice President of Marketing, effective immediately. "We are excited to welcome Katie and Brett to our team. Katie brings an understanding of the neurostimulation ma

      9/4/24 4:05:00 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care